Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?

Inge M. van der Sluis; Yves Bertrand; André Baruchel; Rob Pieters

doi:10.1111/bjh.18372

Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?

Inge M. van der Sluis, Yves Bertrand, André Baruchel, Rob Pieters

Group Pieters

Research output: Contribution to journal › Letter › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	e82-e83
Journal	British Journal of Haematology
Volume	198
Issue number	6
DOIs	https://doi.org/10.1111/bjh.18372
Publication status	Published - Sept 2022

Keywords

Antineoplastic Agents/therapeutic use
Asparaginase/therapeutic use
Erythrocytes
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy

Access to Document

10.1111/bjh.18372

Cite this

@article{295a54b25a7f4f689e5e92a1a9a37452,

title = "Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?",

keywords = "Antineoplastic Agents/therapeutic use, Asparaginase/therapeutic use, Erythrocytes, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy",

author = "{van der Sluis}, {Inge M.} and Yves Bertrand and Andr{\'e} Baruchel and Rob Pieters",

note = "Funding Information: All authors contributed to the writing.",

year = "2022",

month = sep,

doi = "10.1111/bjh.18372",

language = "English",

volume = "198",

pages = "e82--e83",

journal = "British Journal of Haematology",

issn = "0007-1048",